Avantra Biosciences Starts Shipments of Q400 Biomarker Workstation | GenomeWeb

Avantra Biosciences announced this week the first shipments of its Q400 Biomarker Workstation and Angio Qx BioChip immunoassay for the study of tumor vascularization.

The shipments mark the culmination of the long journey back to the market for the platform. Originally developed by defunct biotech firm Decision Biomarkers, the platform was purchased in bankruptcy court with the rest of Decision's assets in December 2009 by Courtagen Capital Group, which launched Avantra in July of last year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.